{"page_content": "27 Amgen 2010 Environmental Sustainability ReportAmgen Inc.\nReconciliation of GAAP Net Income to \u201cAdjusted\u201d Net Income (Unaudited) ($ in billions) \nResults for the years ended December 31,  2010  2009  2008  2007\nGAAP net income  $4.627  $4 .605 $4 .052 $3 .078\nAdjustments to GAAP net income:\nAmortization of acquired intangible assets, product technology rights  0.294(a) 0 .294(a) 0 .294(a) 0 .295(a)\nIncremental non-cash interest expense  0.266(b) 0 .250(b) 0 .235(b) 0 .219(b)\nStock option expense  0.124(c) 0 .115(c) 0 .103(c) 0 .181(c)\nAsset impairment charge  0.118(d) \u2014 \u2014 \u2014\nAmortization of acquired intangible assets, research and development (R&D) technology rights  0.070(e) 0 .070(e) 0 .070(e) 0 .071(e)\nLegal settlements  (0.001)(f) 0 .033(f) 0 .288(f) 0 .034(f)\nRestructuring and related costs  \u2014 0 .070(g) 0 .148(g) 0 .739(g)\nWrite-off of inventory  \u2014 \u2014 0 .084(h) 0 .090(h)\nWrite-off of acquired in-process R&D  \u2014 \u2014 \u2014 0 .590(i)\nOther merger-related expenses  \u2014 \u2014 0 .001(j) 0 .036(j)\nWrite-off of manufacturing asset  \u2014 \u2014 \u2014 0 .030(k)\nOther  \u2014 \u2014 \u2014 0 .024\n 0.871  0 .832 1 .223 2 .309\nTax effect of the above adjustments  (0.318)(l) (0 .293)(l) (0 .390)(l) (0 .491)(l)\nTax settlement  (0.151)(m) (0 .087)(m) \u2014 (0 .092)(m)\nTax benefit resulting from prior-period charges  (0.005)(n) (0 .018)(n) \u2014 \u2014\nCalifornia tax law change  \u2014 (0 .025)(o) \u2014 \u2014\n\u201cAdjusted\u201d net income  $5.024  $5 .014 $4 .885 $4 .804\n \n \nReconciliation of GAAP R&D Expense to \u201cAdjusted\u201d R&D (Unaudited) ($ in billions)   \nResults for the years ended December 31,  2010  2009  2008  2007\nGAAP R&D expense  $2.894  $2 .864 $3 .030 $3 .266\nAdjustments to GAAP R&D expense:\nStock option expense  (0.051)(c) (0 .049)(c) (0 .046)(c) (0 .083)(c)\nAmortization of acquired intangible assets, R&D technology rights  (0.070)(e) (0 .070)(e) (0 .070)(e) (0 .071)(e)\nRestructuring and related costs  \u2014 (0 .006)(g) (0 .003)(g) (0 .019)(g)\nOther merger-related expenses  \u2014 \u2014 (0 .001)(j) (0 .029)(j)\n\u201cAdjusted\u201d R&D expense  $2.773  $2 .739 $2 .910 $3 .064\n(a)  To exclude the ongoing, non-cash amortization of acquired product technology rights, primarily ENBREL, related \nto the Immunex Corporation acquisition in 2002  .\n(b)  To exclude the incremental non-cash interest expense resulting from a change in the accounting for our \nconvertible notes effective January 1, 2009  .\n(c)  To exclude stock option expense  . \n(d)  To exclude an asset impairment charge associated with the transaction announced in January 2011 involving \nour manufacturing operation in Fremont, California  .\n(e)  To exclude the ongoing, non-cash amortization of the R&D technology intangible assets acquired with \nalternative future uses with the 2006 acquisitions of Abgenix, Inc  . (Abgenix) and Avidia, Inc  . (Avidia)  .\n(f)  To exclude loss accruals or awards for legal settlements  .\n(g)  To exclude restructuring and related cost savings initiative charges  .\n(h)  To exclude the write-off of inventory resulting from, in 2008, a strategic decision to change manufacturing \nprocesses and, in 2007, changing regulatory and reimbursement environments  .\n(i)  To exclude the non-cash expense associated with writing off the acquired in-process R&D related to the \nacquisitions of Alantos Pharmaceutical Holding, Inc  . (Alantos) and Ilypsa, Inc  . (Ilypsa) in 2007  .\n(j)  To exclude merger-related expenses incurred due to the acquisitions of Alantos, Ilypsa and Abgenix and,  \nalso for 2007 Tularik Inc  . These expenses related primarily to incremental costs associated with retention  \nand integration  .(k)  To exclude the write-off of the cost of a semi-completed manufacturing asset that will not be used due to a \nchange in manufacturing strategy  .\n(l)  To exclude the tax effect of the above adjustments  . The tax provision (benefit) for the adjustments between our \nGAAP and \u201cAdjusted\u201d results takes into account the tax treatment and related tax rate(s) that apply to each \nadjustment in the applicable tax jurisdiction(s)  . Generally, this results in a tax impact at the U  .S . marginal tax \nrate for certain adjustments, including amortization of intangible assets and non-cash interest expense \nassociated with our convertible notes, whereas the tax impact of other adjustments, including impairments, \nstock option expense and restructuring-related items, depends on whether the amounts are deductible in the \ntax jurisdictions where the asset is located or the expenses are incurred and the applicable tax rate(s) in those \njurisdictions  .\n(m)  To exclude the net tax benefit recognized as the result of resolving certain transfer pricing issues with tax \nauthorities for prior periods  .\n(n) To exclude the tax benefit related principally to certain prior-period charges excluded from \u201cAdjusted\u201d earnings  .\n(o)  To exclude the net tax benefit resulting from adjustments to previously established deferred taxes, related \nprimarily to prior acquisitions and stock option expense, due to changes in California tax law effective in 2011  .Notes:", "metadata": {"source": "NASDAQ_AMGN_2010.pdf", "page": 26, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}